Kura Oncology, Inc. (NASDAQ:KURA) Receives $25.50 Average Target Price from Analysts

Shares of Kura Oncology, Inc. (NASDAQ:KURA) have been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.50.

Several equities research analysts have commented on KURA shares. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research note on Thursday, November 21st. BTIG Research cut Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Scotiabank cut their target price on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. Finally, StockNews.com cut Kura Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday.

Kura Oncology Stock Down 1.0 %

Shares of Kura Oncology stock opened at $7.27 on Friday. Kura Oncology has a 1 year low of $6.79 and a 1 year high of $23.48. The business has a 50-day moving average of $7.81 and a two-hundred day moving average of $12.61. The company has a market capitalization of $587.09 million, a P/E ratio of -3.08 and a beta of 0.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. As a group, equities analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Insider Buying and Selling

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the sale, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Several large investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its position in shares of Kura Oncology by 11.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,489 shares of the company’s stock worth $144,000 after buying an additional 1,750 shares during the last quarter. Rhumbline Advisers lifted its position in shares of Kura Oncology by 2.0% during the 4th quarter. Rhumbline Advisers now owns 99,991 shares of the company’s stock worth $871,000 after buying an additional 1,923 shares during the last quarter. Harbor Capital Advisors Inc. lifted its position in shares of Kura Oncology by 4.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the last quarter. Teacher Retirement System of Texas raised its position in Kura Oncology by 19.9% in the fourth quarter. Teacher Retirement System of Texas now owns 13,749 shares of the company’s stock valued at $120,000 after purchasing an additional 2,285 shares during the last quarter. Finally, MetLife Investment Management LLC raised its position in Kura Oncology by 6.6% in the fourth quarter. MetLife Investment Management LLC now owns 44,828 shares of the company’s stock valued at $390,000 after purchasing an additional 2,776 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.